Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Torben PlesnerSimon J HarrisonHang QuachCindy LeeAdam BryantAnnette VangstedJane EstellMichel DelforgeFritz OffnerPatrick TwomeyVoleak ChoeurngJunyi LiRobert HendricksShannon M RuppertTeiko SumiyoshiKaren MillerEunpi ChoFredrik SchjesvoldPublished in: Clinical hematology international (2023)
gov/ct2/show/NCT04434469 .